Foghorn Therapeutics (FHTX) Income from Non-Controlling Interests (2020 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Income from Non-Controlling Interests came in at -$157000.0 in Q1 2026, down 29.75% year-on-year from -$223494.1 in Q1 2025, and down 330.88% quarter-over-quarter from $68000.0 in Q3 2025.
Foghorn Therapeutics (FHTX) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$157000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 29.75% year-over-year to -$157000.0 in Q1 2026; TTM through Mar 2026 was -$147000.0, a 128.77% decrease from a year earlier, with the FY2025 full-year figure at -$111000.0, down 111.55% from the prior year.
- Income from Non-Controlling Interests retreated to -$157000.0 in Q1 2026 per FHTX's latest filing, from $68000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.1 million in Q1 2023 and bottomed at -$2.0 million in Q2 2022.
- The 5-year median for Income from Non-Controlling Interests is $109500.0 (2023), against an average of -$7687.5.
- Biggest YoY gain for Income from Non-Controlling Interests was 29166.67% in 2022; the steepest drop was 55733.33% in 2022.
- Year by year, Income from Non-Controlling Interests stood at $878000.0 in 2022, then rose by 21.53% to $1.1 million in 2023, then slumped by 121.09% to -$225000.0 in 2024, then soared by 130.22% to $68000.0 in 2025, then sank by 330.88% to -$157000.0 in 2026.
- Per Business Quant, the three latest FHTX Income from Non-Controlling Interests figures stand at -$157000.0 (Q1 2026), $68000.0 (Q3 2025), and -$58000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | -157,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Jun 30, 2025 | -58,000.00 |
| Mar 31, 2025 | -121,000.00 |
| Dec 31, 2024 | -225,000.00 |
| Sep 30, 2024 | 698,000.00 |
| Jun 30, 2024 | 159,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Dec 31, 2023 | 1.07 Mn |
| Sep 30, 2023 | 826,000.00 |
| Jun 30, 2023 | 151,000.00 |
| Mar 31, 2023 | 1.12 Mn |
| Dec 31, 2022 | 878,000.00 |
| Sep 30, 2022 | -1.68 Mn |
| Jun 30, 2022 | -2.00 Mn |
| Mar 31, 2022 | -1.18 Mn |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -16,000.00 |
| Mar 31, 2021 | 13,000.00 |